Onitraz-Forte Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent effective against a wide range of fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This medication is indicated for the treatment of various systemic and superficial mycoses, including blastomycosis, histoplasmosis, aspergillosis, onychomycosis, and other dermatophytic infections. Onitraz-Forte is particularly useful in patients who require oral antifungal therapy with enhanced bioavailability and sustained plasma concentrations. The capsule formulation ensures convenient administration and optimal absorption when taken with food. Dosage and duration of therapy should be individualized based on the type and severity of infection, as well as patient response. Caution is advised in patients with hepatic impairment or congestive heart failure, and potential drug interactions must be carefully monitored due to Itraconazole’s effect on cytochrome P450 enzymes. Common adverse effects include gastrointestinal disturbances, headache, and rash. Regular monitoring of liver function tests is recommended during prolonged therapy. Onitraz-Forte Capsule should be used under medical supervision to ensure safe and effective treatment outcomes.